Sai Duriseti • UCLA Profiles (original) (raw)

  1. Direct-to-Unit Stereotactic Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy for Spine Metastasis. Int J Radiat Oncol Biol Phys. 2026 Apr 01; 124(5):1233-1238. Liu W, Morris ED, Schiff JP, Laugeman E, Price AT, Green O, Miller K, Jansen B, Duriseti S, Rudra S, Badiyan SN, Samson PP, Kim H, Henke LE, Robinson CG. PMID: 41325873.
    View in: PubMed Mentions: Fields:
  2. ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide. Am J Clin Oncol. 2026 Feb 01; 49(2):51-61. Trout AT, Boike TP, Avram AM, Barry P, Dadparvar S, Duriseti S, Flavell RR, Grant FD, Kwatra N, Lai HA, Parisi MT, Yom SS, Tulchinsky M, Ghesani MV, Subramaniam RM, Levin TL, Small W, Schechter NR. PMID: 40694360.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  3. Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. 2025 Aug; 8(4):893-898. Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriseti S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. PMID: 40541485; PMCID: PMC12311854.
    View in: PubMed Mentions: Fields:
    Translation:HumansCTClinical Trials
  4. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease. Eur Urol Oncol. 2025 Jun; 8(3):700-708. Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. PMID: 39521638.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  5. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer. World J Urol. 2024 Mar 16; 42(1):165. Nikitas J, Kishan A, Chang A, Duriseti S, Nichols NG, Reiter R, Rettig M, Brisbane W, Steinberg ML, Valle L. PMID: 38492111.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  6. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024 Aug; 86(2):190-193. Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. PMID: 38490853; PMCID: PMC12363338.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  7. A Dose Accumulation Assessment of Alignment Errors During Spatially Fractionated Radiation Therapy. Pract Radiat Oncol. 2024 Jul-Aug; 14(4):e283-e290. Ginn J, Duriseti S, Mazur T, Spraker M, Kavanaugh J. PMID: 38081359.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  8. Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement. Eur J Hybrid Imaging. 2023 Apr 03; 7(1):7. Duriseti S, Berenji G, Tsai S, Rettig M, Nickols NG. PMID: 37009941; PMCID: PMC10068685.
    View in: PubMed Mentions: 1
  9. Better Late than Never for Late Toxicity Assessment. Eur Urol. 2023 May; 83(5):391-392. Duriseti S, Berenji GR, Nickols NG, Rettig MB. PMID: 36797143.
    View in: PubMed Mentions: Fields:
  10. Brainstem Toxicity in Pediatric Patients Treated with Protons Using a Single-vault Synchrocyclotron System. Int J Part Ther. 2022; 9(1):12-17. Orukari I, Perkins S, Zhao T, Huang J, Caruthers DF, Duriseti S. PMID: 35774490; PMCID: PMC9238130.
    View in: PubMed Mentions: 5
  11. LITE SABR M1: Planning design and dosimetric endpoints for a phase I trial of lattice SBRT. Radiother Oncol. 2022 02; 167:172-178. Kavanaugh JA, Spraker MB, Duriseti S, Basarabescu F, Price A, Goddu M, Knutson N, Prusator M, Robinson C, Mazur T. PMID: 34896459.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansCTClinical Trials
  12. LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiother Oncol. 2022 02; 167:317-322. Duriseti S, Kavanaugh JA, Szymanski J, Huang Y, Basarabescu F, Chaudhuri A, Henke L, Samson P, Lin A, Robinson C, Spraker MB. PMID: 34875286.
    View in: PubMed Mentions: 27 Fields:
    Translation:HumansCTClinical Trials
  13. Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2022 Jan-Feb; 7(1):100797. Schiff JP, Spraker MB, Duriseti S, Shaikh S, Murad HF, Mutch DG, Robinson CG, Kavanaugh J, Lin AJ. PMID: 34761139; PMCID: PMC8567179.
    View in: PubMed Mentions: 11
  14. Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Adv Radiat Oncol. 2021 May-Jun; 6(3):100639. Duriseti S, Kavanaugh J, Goddu S, Price A, Knutson N, Reynoso F, Michalski J, Mutic S, Robinson C, Spraker MB. PMID: 34195486; PMCID: PMC8233471.
    View in: PubMed Mentions: 46
  15. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018 Dec; 140(3):629-638. Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S. PMID: 30206764.
    View in: PubMed Mentions: 48 Fields:
    Translation:Humans
  16. Brain metastasis growth on preradiosurgical magnetic resonance imaging. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):e369-e376. Garcia MA, Anwar M, Yu Y, Duriseti S, Merritt B, Nakamura J, Hess C, Theodosopoulos PV, McDermott M, Sneed PK, Braunstein SE. PMID: 30174247.
    View in: PubMed Mentions: 13 Fields:
    Translation:Humans
  17. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes. J Neurosurg. 2017 Jun; 126(6):1756-1763. Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess CP, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott M, Sneed PK, Braunstein S. PMID: 27367235.
    View in: PubMed Mentions: 6 Fields:
    Translation:Humans
  18. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014; 4(3):267-79. LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. PMID: 24505235; PMCID: PMC3915090.
    View in: PubMed Mentions: 20 Fields:
    Translation:HumansAnimalsCells
  19. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013 Apr 01; 73(7):2070-81. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. PMID: 23400595; PMCID: PMC3618559.
    View in: PubMed Mentions: 47 Fields:
    Translation:HumansAnimalsCells
  20. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem. 2010 Aug 27; 285(35):26878-26888. Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. PMID: 20501655; PMCID: PMC2930687.
    View in: PubMed Mentions: 38 Fields:
    Translation:HumansAnimalsCells
  21. Molecular basis of binding of the Plasmodium falciparum receptor BAEBL to erythrocyte receptor glycophorin C. Mol Biochem Parasitol. 2009 Nov; 168(1):49-54. Jiang L, Duriseti S, Sun P, Miller LH. PMID: 19563830; PMCID: PMC2744354.
    View in: PubMed Mentions: 17 Fields:
    Translation:HumansAnimalsCells
  22. HOXA5 regulates hMLH1 expression in breast cancer cells. Neoplasia. 2006 Apr; 8(4):250-8. Duriseti S, Winnard PT, Mironchik Y, Vesuna F, Raman A, Raman V. PMID: 16756717; PMCID: PMC1600677.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansAnimalsCells
  23. The effect of metaproterenol in chronic asthmatic children receiving therapeutic doses of theophylline. J Allergy Clin Immunol. 1978 Feb; 61(2):73-9. Galant SP, Groncy CE, Duriseti S, Strick L. PMID: 340493.
    View in: PubMed Mentions: 3 Fields:
    Translation:HumansCTClinical Trials
  24. Allergy-epitomes of progress: immunologic aspects of atopic dermatitis. West J Med. 1977 Nov; 127(5):409. Galant SP, Duriseti S. PMID: 18748085; PMCID: PMC1237885.
    View in: PubMed Mentions: Fields:

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs